Press Release

15 April 2011

LIDCO GROUP PLC

("LiDCO" or the "Company")

NOTIFICATION OF MAJOR INTEREST IN SHARES

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESⁱ

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ⁱⁱ		Lidco Group PLC
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights			YES
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached			NO
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments			NO
An event changing the breakdown of voting rights			NO
Other (please specify):			NO
3. Full name of person(s) subject to the notification obligation: ⁱⁱⁱ	Ingalls & Snyder LLC ("I&S") and Ingalls & Snyder Value Partners LP ("ISVP").
4. Full name of shareholder(s) (if different from 3.):^iv	I&S, on behalf of its clients, has dispositive authority over (i.e. the power and authorization to sell at I&S's discretion) 24,424,368 shares. In respect of 13,820,000 of such 24,424,368 shares ISVP (as beneficial owner) shares dispositive authority with I&S and has voting authority. So in respect of the 13,820,000 shares beneficially held by ISVP, I&S has and ISVP share dispositive authority and ISVP has voting authority.
5. Date of the transaction and date on which the threshold is crossed or reached:^v	April 13, 2011
6. Date on which issuer notified:	April 14, 2011
7. Threshold(s) that is/are crossed or reached: ^{vi, vii}	Interest in excess of 14% of issued share capital.

8. Notified details:

A: Voting rights attached to shares ^{viii, ix}

Class/type of
shares

if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of voting rights ^x

Direct

Direct ^xi

Indirect ^xii

Direct

Indirect

Ordinary Shares of 0.5 pence ISIN GB0030546849

23,855,746

24,424,368

See note 4 above. I&S has dispositive authority over 24,424,368 shares and ISVP has voting authority and shares dispositive authority in respect of 13,820,000 of such shares.

14.04% (Note: For these purposes we have assumed that dispositive authority is equivalent to voting rights).

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date ^xiii

Exercise/
Conversion Period ^xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

N/A

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments ^{xv, xvi}

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date ^xvii

Exercise/
Conversion period ^xviii

Number of voting rights instrument refers to

% of voting rights ^{xix, xx}

N/A

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

24,424,368 (Note: For these purposes we have assumed that dispositive authority is equivalent to voting rights).

14.04% (Note: For these purposes we have assumed that dispositive authority is equivalent to voting rights).

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: ^xxi
N/A

Proxy Voting:
10. Name of the proxy holder:		N/A
11. Number of voting rights proxy holder will cease to hold:		N/A
12. Date on which proxy holder will cease to hold voting rights:		N/A

13. Additional information:
14. Contact name:	Frank Stolba
15. Contact telephone number:	(001) (212) 269 - 7814

- Ends -

For further information, please contact:

LiDCO Group Plc
Terry O'Brien (CEO)	Tel: +44 (0)20 7749 1500
Paul Clifford (Finance Director)
Theresa Wallis (Chairman)	www.lidco.com

FinnCap

Geoff Nash / Henrik Persson

Stephen Norcross (broking)

Tel: +44 (0)20 7600 1658

www.finncap.com

Media enquiries:

Abchurch

Adam Michael / Joanne Shears /

Simone Elviss / Claire Dickinson

Tel: +44 (0) 20 7398 7728

simone.elviss@abchurch-group.com

www.abchurch-group.com

About LiDCO Group Plc

LiDCO is a supplier of minimally invasive hemodynamic equipment to hospitals, to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the measurement, analysis, audit, training and sharing of real-time and historic hemodynamic data, in both critical care units and the operating theatre.

Scientific evidence is increasingly linking the optimisation of patients' hemodynamic status with better outcomes and reduced hospital stays and LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%)
LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anesthetists to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides:
·	early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug
·	quantification of hemodynamic response,
·	guidance on effective delivery of fluids to ensure the right amount at the right time
LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

All LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

Clinical Validation & Education

LiDCO has been selected as the sole technology for two ongoing multi-centre government-funded studies in the UK and US. OPTIMISE is sponsored by the UK Government for optimising cardiovascular management in high-risk abdominal surgery patients and in the US, MOnIToR is a US Government sponsored transplantation donor organ optimisation study. The Company has also developed a hemodynamic workshop at St George's Hospital, London.

LiDCO Distribution Network:

LiDCO products are sold through Covidien's sales force in the US. LiDCO's strategy is to sell directly to hospitals in the UK, and through a network of specialty critical care and anesthesia distributors in the rest of the world.

LiDCO's sales office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM. For more information please see www.lidco.com.